Incretin therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is), are efficacious modern therapies for type 2 diabetes which will offer multifactorial clinical benefits. The gene discussed is GCG; the disease is type 2 diabetes mellitus.